

Peter Zweifel · Friedrich Breyer · Mathias Kifmann

# Health Economics

Second Edition

 Springer

---

## Detailed Table of Contents

Preface .....	v
Contents Overview .....	vii
<b>1 Introduction</b> .....	<b>1</b>
1.1 Health – a Priceless Commodity? .....	1
1.2 The Micro- and Macroeconomic Views of Health .....	3
1.2.1 A Simplified Microeconomic View of Health .....	3
1.2.2 Health Care at the Macroeconomic Level .....	6
1.2.3 A Critique of Global Budgeting .....	7
1.3 ‘Economics of Health’ vs. ‘Economics of Health Care’ .....	10
1.3.1 Economics of Health .....	10
1.3.2 Health and the Use of Health Care Services .....	11
1.3.3 Economics of Health Care .....	11
1.4 A System Analysis of the Economics of Health and Health Care ...	12
1.5 Summary .....	15
<b>2 Economic Valuation of Life and Health</b> .....	<b>17</b>
2.1 Introduction .....	17
2.2 Approaches to the Economic Evaluation of Health .....	18
2.3 Cost-Utility Analysis .....	25
2.3.1 Concepts of Utility Measurement .....	25

2.3.2	The QALY Concept .....	26
2.3.2.1	Calculating QALYs .....	26
2.3.2.2	Decision-Theoretic Foundation .....	28
2.3.2.3	QALYs and Consumption .....	32
2.3.2.4	Aggregation of QALYs and Collective Decision-Making .....	34
2.3.3	Evaluating Health States .....	36
2.3.3.1	Rating Scale .....	36
2.3.3.2	Time Trade-Off .....	36
2.3.3.3	Standard Gamble .....	38
2.4	Cost-Benefit Analysis .....	40
2.4.1	Ethical Objections and Counterarguments .....	40
2.4.1.1	Objections Against Weighing Life Against Money	40
2.4.1.2	Arguments Against a Finite Value of Life .....	42
2.4.2	The Human-Capital Approach .....	43
2.4.3	The Willingness-To-Pay Approach .....	45
2.4.4	Aggregating Willingness To Pay and Principles of Collective Decision-Making .....	47
2.4.4.1	Cost-Benefit Analysis and the Potential Pareto Criterion .....	48
2.4.4.2	Cost-Benefit Analysis with Many Interventions ...	49
2.4.4.3	Cost-Benefit Analysis and Social Welfare Analysis	49
2.4.5	Measuring Willingness To Pay: Using Surveys .....	54
2.4.5.1	General Problems of Surveys .....	54
2.4.5.2	The Contingent Valuation Method .....	55
2.4.5.3	Discrete Choice Experiments .....	58
2.4.6	Measuring Willingness to Pay: Using Market Data .....	61
2.5	Cost-Utility, Cost-Benefit and Social Welfare Analysis .....	63
2.5.1	Comparing Cost-Utility and Cost-Benefit Analysis .....	63
2.5.2	Social Welfare and QALYs .....	66
2.6	Summary .....	69
2.7	Further Reading .....	70
2.E	Exercises .....	71

<b>3</b>	<b>Individuals as Producers of Their Health</b> .....	75
3.1	Introduction .....	75
3.2	The Concept of Health Production .....	77
3.3	Health as Part of Human Capital .....	79
3.3.1	A Simplified Grossman Model .....	79
3.3.2	The Demand for Health and Medical Services .....	83
3.3.2.1	The Structural Demand Function for Medical Services .....	83
3.3.2.2	The Demand Functions in the Investment Model ..	84
3.3.2.3	The Demand Functions in the Consumption Model	85
3.3.3	Preliminary Assessment of the Grossman Model .....	86
3.4	The Production of Health as the Modification of a Stochastic Process	89
3.4.1	Conditional Health Production Functions .....	89
3.4.2	Short-run Optimization and Willingness to Pay for Health ..	91
3.4.3	A Model with State-Dependent Production Possibilities: The Short Term .....	94
3.4.3.1	State-Dependent Optimization of a Stochastic Process .....	94
3.4.3.2	The Elements of the Model .....	96
3.4.3.3	Conditional Short-term Production Frontiers .....	98
3.4.3.4	Alleged Instability of Health Behavior .....	101
3.4.4	State-Dependent Production Possibilities: The Longer Run ..	103
3.4.4.1	The Longer-Run Trade-Off Given Good Health ...	104
3.4.4.2	The Longer-Run Trade-Off Given Bad Health ....	106
3.4.5	Complementarity or Substitutability in the Production of Health? .....	107
3.4.5.1	Significance of the Issue .....	107
3.4.5.2	Substitutability in the Healthy State .....	108
3.4.5.3	Complementarity in the Sick State .....	109
3.5	Summary .....	109
3.6	Further Reading .....	110
3.A	Appendix to Chapter 3 .....	111
3.E	Exercises .....	118

<b>4</b>	<b>Empirical Studies of the Production of Health</b> . . . . .	119
4.1	Introduction . . . . .	119
4.2	Studies Based on Aggregate Data . . . . .	121
4.2.1	Mortality Rates and Life Expectancy as Measures of Output? . . . . .	121
4.2.2	Marginal Productivity of a Health Care System . . . . .	122
4.2.2.1	Early Evidence from the United States . . . . .	122
4.2.2.2	Recent Evidence from the United States . . . . .	127
4.2.2.3	Evidence from Industrialized Countries . . . . .	129
4.2.2.4	Evidence from a Comparison of Two Neighboring Areas . . . . .	131
4.2.2.5	Evidence from a Developing Region (Sub-Saharan Africa) . . . . .	132
4.2.3	Marginal Productivity of Selected Medical Interventions . . . . .	135
4.2.4	Environmental Determinants of Health Status . . . . .	136
4.2.5	Economic Instability and Health . . . . .	137
4.3	Studies Based on Individual Data . . . . .	140
4.3.1	Measurement of Health Status . . . . .	140
4.3.2	Marginal Productivity of Medical Infrastructure at the Individual Level . . . . .	141
4.3.3	The Productivity of Medical Interventions at the Individual Level . . . . .	142
4.3.4	Environmental Quality and the State of Health . . . . .	143
4.3.4.1	Air Quality and Smoking as Exogenous Factors . . . . .	143
4.3.4.2	Smoking as an Endogenous Factor . . . . .	146
4.4	Demand for Health, Demand for Health Services . . . . .	148
4.5	Summary . . . . .	152
4.6	Further Reading . . . . .	152
4.E	Exercises . . . . .	153
<b>5</b>	<b>Health Goods, Market Failure and Justice</b> . . . . .	155
5.1	Introduction . . . . .	155
5.2	Market Failure in Markets for Health Goods . . . . .	157
5.2.1	Externalities and the Problem of Public Goods . . . . .	157
5.2.2	Option-Good Property of Medical Services . . . . .	159

5.2.3	Lack of Consumer Sovereignty . . . . .	160
5.2.3.1	Incapability of Rational Decision Making . . . . .	160
5.2.3.2	Excess Discounting of Future Needs . . . . .	161
5.2.4	Lack of Perfect Information in Markets for Health Goods . .	161
5.3	Market Failure in Health Insurance Markets . . . . .	163
5.3.1	The Basic Model . . . . .	163
5.3.2	The Free-Rider Problem . . . . .	166
5.3.3	Asymmetric Information in the Health Insurance Market . . .	171
5.3.3.1	Risk Types . . . . .	171
5.3.3.2	Market Equilibrium under Symmetric Information	172
5.3.3.3	Market Equilibrium under Asymmetric Information	173
5.3.3.4	Welfare-Enhancing Government Intervention in Insurance Markets . . . . .	176
5.3.3.5	Alternative Equilibrium Definitions . . . . .	178
5.3.4	Premium Risk . . . . .	180
5.3.4.1	Pure-Market Solutions . . . . .	181
5.3.4.2	Community Rating as a Solution . . . . .	185
5.3.4.3	Comparing the Solutions . . . . .	187
5.4	Justice as an Argument in Favor of Government Intervention in Health Care . . . . .	189
5.4.1	Willingness and Ability to Pay and Access to Health Care . .	189
5.4.2	Congenital Differences in Health and Access to Health Insurance . . . . .	192
5.4.2.1	Redistribution and the Veil of Ignorance . . . . .	192
5.4.2.2	Implementing Cross-Subsidies between High and Low Risks . . . . .	193
5.5	Rationing of Health Care Services . . . . .	194
5.5.1	The Concept of Rationing . . . . .	195
5.5.2	Types of Primary Rationing . . . . .	196
5.6	Summary . . . . .	198
5.7	Further Reading . . . . .	199
5.E	Exercises . . . . .	200

<b>6</b>	<b>Optimal Health Insurance Contracts</b> .....	203
6.1	Introduction .....	203
6.2	Types of Health Insurance Contracts .....	205
6.3	Optimal Insurance Protection in the Absence of Moral Hazard .....	208
6.3.1	Financial Consequences of Illness Only .....	208
6.3.1.1	A Model with Two Health States .....	209
6.3.1.2	A Model with an Arbitrary Number of Health States .....	215
6.3.2	Direct Utility Effects of Illness .....	221
6.3.3	Summary .....	224
6.4	Optimal Insurance Coverage with Moral Hazard .....	224
6.4.1	Ex-Ante Moral Hazard .....	224
6.4.1.1	Assumptions .....	224
6.4.1.2	Optimal Prevention without Insurance .....	226
6.4.1.3	The Optimum with Observable Prevention .....	227
6.4.1.4	The Optimum with Unobservable Prevention .....	228
6.4.1.5	Implications .....	232
6.4.1.6	Empirical Evidence on Ex-Ante Moral Hazard .....	232
6.4.2	Ex-Post Moral Hazard .....	233
6.4.2.1	Assumptions .....	233
6.4.2.2	Optimal Insurance Coverage with Observable State of Health .....	235
6.4.2.3	Optimal Insurance Coverage with Unobservable State of Health .....	237
6.4.2.4	Implications .....	241
6.4.2.5	The Empirical Relationship Between Insurance Coverage and the Demand for Health Care Services .....	242
6.5	Consequences for the Design of Social Health Insurance .....	244
6.6	Summary .....	246
6.7	Further Reading .....	247
6.A	Appendix .....	248
6.E	Exercises .....	250

<b>7</b>	<b>Risk Selection in Health Insurance Markets</b> .....	253
7.1	Introduction .....	253
7.2	Modeling Risk Selection .....	255
7.2.1	Direct Risk Selection .....	255
7.2.2	Indirect Risk Selection .....	257
7.2.2.1	Indirect Risk Selection Using the Quantity of Benefits .....	259
7.2.2.2	Risk Selection Using the Structure of Benefits ....	270
7.3	Further Arguments in Favor of Risk Adjustment and Cost Reimbursement .....	276
7.3.1	Fair Competition in the Health Insurance Market .....	277
7.3.2	Stabilization of the Health Insurance Market .....	277
7.4	Designing Risk Adjustment Schemes .....	278
7.4.1	An Overview of Risk Adjusters .....	278
7.4.2	Costs and Payment Flows .....	280
7.4.3	Calculating Risk Adjustment Payments .....	282
7.4.3.1	The Statistical Approach to Risk Adjustment .....	282
7.4.3.2	The Incentive Approach to Risk Adjustment .....	283
7.5	Designing Cost Reimbursement Schemes .....	284
7.5.1	The Basis of Cost Reimbursement .....	285
7.5.2	The Structure of Cost Reimbursement .....	285
7.5.3	Findings of Empirical Studies .....	286
7.6	Summary .....	287
7.7	Further Reading .....	289
7.E	Exercises .....	290
<b>8</b>	<b>Physicians as Suppliers of Medical Services</b> .....	293
8.1	Introduction .....	293
8.2	The Relationship Between Physician Density and the Utilization of Medical Services .....	294
8.3	The Hypothesis of Supplier-Induced Demand for Ambulatory Medical Services .....	295



8.4	Utility Maximization of the Physician and Supplier-Induced Demand	298
8.4.1	A Model of Physician Behavior	298
8.4.2	Increasing Physician Density	300
8.4.3	Increasing Fee Level	304
8.5	Physician Density and Utilization of Medical Services: Alternative Explanations	304
8.6	Empirical Examination of the Supplier-Induced Demand Hypothesis	306
8.6.1	Physician Density and Volume of Services	306
8.6.2	Regulated Fees and Volume of Services	307
8.7	Summary	308
8.8	Further Reading	309
8.E	Exercises	309
<b>9</b>	<b>Hospital Services and Efficiency</b>	<b>311</b>
9.1	Introduction	311
9.2	The Hospital as a Productive Unit	312
9.2.1	Hospital Output: Health as a Latent Variable	312
9.2.2	The Multi-Stage Character of Production in the Hospital	313
9.2.3	The Heterogeneity of Hospital Output	317
9.3	Comparing Hospital Efficiency	318
9.3.1	Regulation and Asymmetric Information	318
9.3.2	Hospital Cost Functions	319
9.3.3	Data Envelopment Analysis	322
9.3.3.1	Introduction	322
9.3.3.2	Comparing the Efficiency of Swiss Hospitals	324
9.3.4	Potential and Limits of Efficiency Measurement	328
9.4	Summary	328
9.5	Further Reading	329
9.E	Exercises	329
<b>10</b>	<b>Paying Providers</b>	<b>331</b>
10.1	Introduction	331
10.2	Paying Providers to Achieve Cost Control	333
10.2.1	The Principle of Full Cost Responsibility	333

10.2.1.1	The Basic Model	333
10.2.1.2	The First-Best Payment System	334
10.2.1.3	Implementing the First-Best Solution	336
10.2.2	Paying Risk-Averse Providers	338
10.2.2.1	Contractible Effort to Control Costs	338
10.2.2.2	Noncontractible Effort to Control Costs	340
10.2.3	Casemix and Information Rent	344
10.2.3.1	Symmetric Information about Casemix	344
10.2.3.2	Asymmetric Information about Casemix	344
10.3	Concerns Beyond Cost Control	348
10.3.1	Quality of Treatment	348
10.3.1.1	Extending the Basic Model	348
10.3.1.2	Verifiable Quality or Treatment Outcomes	350
10.3.1.3	Unverifiable Quality and Treatment Outcomes	351
10.3.2	Patient Selection	355
10.3.2.1	Extending the Basic Model	356
10.3.2.2	Symmetric Information about Patients' Cost Types	358
10.3.2.3	Asymmetric Information about Patients' Cost Types	359
10.4	Implications for the Design of Payment Systems	363
10.4.1	General Considerations	363
10.4.2	Paying Physicians	365
10.4.2.1	Overview of Payment Systems	365
10.4.2.2	Optimal Physician Payment	366
10.4.3	Paying Hospitals	368
10.4.3.1	Overview of Payment Systems	368
10.4.3.2	Optimal Hospital Payment	368
10.4.3.3	Hospital Payment Based on Diagnosis Related Groups	370
10.5	Summary	371
10.6	Further Reading	372
10.A	Appendix	372
10.E	Exercises	374

<b>11</b>	<b>Forms of Delivery of Medical Care</b> .....	379
11.1	Introduction .....	379
11.2	The Physician as the Patient's Agent .....	382
11.3	Complementary Principal-Agent Relationships in Health Care .....	384
11.3.1	The Employer as Complementary Agent .....	384
11.3.2	The Government as Complementary Agent .....	384
11.3.2.1	National Health Service .....	385
11.3.2.2	National Health Insurance .....	385
11.3.3	Private Health Insurers as Complementary Agents .....	386
11.4	The Managed Care Organization as an Alternative Form of Provision of Care .....	387
11.4.1	The Managed Care Organization as a Complementary Agent .....	387
11.4.2	Cost Advantages of Managed Care .....	388
11.4.3	Cost Effects of Managed Care Organizations at the System Level .....	390
11.4.4	Final Assessment of Managed Care Organizations .....	395
11.5	Summary .....	396
11.6	Further Reading .....	396
11.A	Appendix .....	397
11.E	Exercises .....	400
<b>12</b>	<b>The Market for Pharmaceuticals</b> .....	401
12.1	Introduction .....	401
12.2	The Development of a New Drug .....	403
12.2.1	The Consumption Technology of a Drug .....	403
12.2.2	Regulation of Market Access by Public Authorities .....	404
12.2.3	Effect of Copayment .....	404
12.3	Pharmaceutical Innovation as an Investment .....	406
12.3.1	The Chronology of a Pharmaceutical Innovation .....	407
12.3.2	Probability of Success and the Cost of Innovation .....	408
12.3.3	Excessive Returns to Pharmaceutical Innovation? .....	410
12.4	The Role of Patent Protection .....	412
12.4.1	Why Patent Protection? .....	412
12.4.2	The Decision Situation of the Innovator .....	413

12.4.3	The Length of Patent Protection from the Regulator's Point of View	416
12.5	Price Regulation of Pharmaceuticals	418
12.5.1	Reasons for Price Regulation	418
12.5.2	The Conflict Between National Regulation and Global Optimization	420
12.5.3	Types of Price Regulation and Their Consequences	422
12.5.3.1	Direct Price Regulation	422
12.5.3.2	Reference Prices	423
12.5.3.3	Rate-of-Return Regulation	423
12.5.3.4	Pharmaceutical Budgets Imposed on Physicians	424
12.6	Price Competition on Pharmaceutical Markets	424
12.7	Summary	427
12.8	Further Reading	427
12.E	Exercises	428
<b>13</b>	<b>The Political Economy of Health Care</b>	429
13.1	Introduction	429
13.2	Collectively Financed Health Care in a Democracy	430
13.2.1	Basic Assumptions	431
13.2.2	The Decision Process	432
13.2.3	Purchase of Private Health Insurance and Demand for Health Care	433
13.2.4	Voting on Public Health Care for a Given Regime	434
13.2.5	Choice of Regime	436
13.2.6	Empirical Implications of the Analysis	437
13.3	The Role of Professional Associations in Health Care	439
13.3.1	Why Are Professional Associations so Important in Health Care?	439
13.3.2	Tasks of Associations in Health Care	441
13.3.3	Competition among Service Providers, Competition among Associations	443
13.4	Summary	445
13.5	Further Reading	445
13.E	Exercises	446

<b>14 Future Challenges to Health Care Systems</b> .....	447
14.1 Introduction .....	447
14.2 The Technological Challenge .....	449
14.2.1 Three Types of Innovation .....	449
14.2.2 Criteria for an Optimal Allocation of Innovative Effort .....	451
14.2.3 Distortions of Criteria at the Aggregate Level .....	454
14.3 The Demographic Challenge .....	457
14.3.1 Ageing of the Population .....	457
14.3.1.1 Improved Control over Health Thanks to Medicine? .....	457
14.3.1.2 The Redistributive Effects of Ageing .....	459
14.3.2 Changes in Household Composition .....	461
14.4 Demographic Ageing, Medical Progress, and Health Care Expenditure .....	462
14.4.1 The ‘Sisyphus Syndrome’ in Health Care .....	463
14.4.1.1 A Simple Dynamic Model of the Sisyphus Syndrome .....	463
14.4.1.2 Empirical Evidence .....	465
14.4.2 Ageing of Population and Health Care Expenditure .....	471
14.4.3 Funding of Health Insurance .....	474
14.5 International Challenges .....	476
14.5.1 Integration of Insurance Markets .....	476
14.5.2 Migration of Health Care Personnel .....	478
14.5.3 Direct International Investment in Hospitals .....	478
14.6 Summary .....	480
14.7 Further Reading .....	482
14.E Exercises .....	482
<b>References</b> .....	483
<b>Author Index</b> .....	505
<b>Subject Index</b> .....	513